Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orbitazine fumarate (SM-1) plus temozolomide in recurrent high-grade glioma
CTR20243217Phase 2Active
- Sponsor
- Shenzhen Zhenxing Pharmaceutical Technology
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orbitazine fumarate in high-grade glioma (HGG), brain glioma, sponsored by Shenzhen Zhenxing Pharmaceutical Technology. Started Oct 2024; status: active.
02
Drugs
orbitazine fumarate
03
Conditions
high-grade glioma (HGG)brain glioma
Beyond the preview
Go deeper on CTR20243217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243217.